Skip to content

Author

E. Antonarakis

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617

Background 177Lu-PSMA-617 radioligand treatment represents a major advancement in the management of metastatic castration-resistant prostate cancer (mCRPC), but key questions remain about tumor-cell dynamics and evolution in patients who have received this drug. Here, we used a circulating tumor cell (CTC) capture assa...

Madeline J. Lee, Lauren Yu, Nicholas A. Zorko et al. · 0 citations
Review Open access Sep 2026

Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.

IMPORTANCE Cardiovascular disease (CVD) is a leading noncancer cause of death among patients with prostate cancer (PC). Population-based risk calculators do not account for treatment-related effects of androgen-deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPis), and they have not been validated...

A. Guha, Ana Barac, M. Ryan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.